| Execution period | 5 years |
|---|
NSE filing, NSE: INDOCO. Summary written from the filing by ALFA Finder's alert engine.
Indoco Remedies Ltd: key numbers
- Share price
- ₹208.30
- Market cap
- ₹1,923 Cr
- Revenue (annual)
- ₹1,845 Cr
- Net profit (annual)
- ₹-95.14 Cr
- P/E (TTM)
- 60.2×Sector 45.9×
- Promoter holding
- 58.92%+0.06% QoQ
- FII holding
- 1.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indoco Remedies Ltd
All →Indoco Remedies Earnings Call Transcript: Key Takeaways
Indoco Remedies hit record quarterly revenue exceeding ₹500 Cr, but faced margin compression from elevated geopolitical freight and material costs.
- Call
- Guides 10% growth
Indoco Remedies Business Update
Indoco's CRO AnaCipher received ANVISA Brazil approval for clinical and bioanalytical facilities. This expands its regulatory footprint to conduct bioequivalence studies in Brazil and Latin America.
Indoco Remedies Q2 FY27 Results: Turns Profitable, Net Profit ₹19.5 Cr
Indoco Remedies Ltd reported revenue from operations of ₹506.9 Cr (+7.4% YoY) and net profit of ₹19.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹19.5 Cr
Indoco Remedies Employee Stock Options
Indoco Remedies allotted 14,850 ESOP shares to its Employees Welfare Trust under the 2022 ESOP plan. The allotment is at face value with no transaction price.
Indoco Remedies Other Announcement
Indoco Remedies Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, in accordance with SEBI Regulation 31(1)(b).
Indoco Remedies Board Meeting Date
Indoco Remedies intimated a board meeting on 27 Oct 2026 to approve Q1 FY27 standalone and consolidated results. Trading window remains closed until 29 Oct 2026.
Other management change announcements
All →Shankara Buildpro Management Change
Shankara Buildpro appointed Whole-time Director Dhananjay Mirlay Srinivas as Managing Director for five years, following the founder's demise. The board outcome reports no financial value.
- Execution
- 5 years (appointment term)
Shankara Building Products Management Change
Shankara Building Products appointed Dhananjay Mirlay Srinivas as Managing Director for five years from November 1, 2026. It follows the death of Founder MD Sukumar Srinivas.
- Execution
- 5 years
Premier Explosives Management Change
Premier Explosives disclosed that Lt. Gen. Peruvemba Ramachandran Kumar ceases as Independent Director on completing his second five-year term, effective close of business on 1 November 2026. The company placed on record its appreciation for his contributions.
Axis Bank Management Change
Axis Bank disclosed that Independent Director Girish Paranjpe ceased to be a director on completion of his tenure, effective close of business on 1 November 2026. No monetary value is involved in this change.
KSB Management Change
KSB Limited announced Uday Joshi's designation as General Manager – Project Contract Management from November 1, 2026. It also disclosed the superannuation cessation of Mukesh Pattewar as Head – Project and Contract Management, effective December 31, 2026.
Oil And Natural Gas Corporation Management Change
ONGC disclosed that Executive Director Sanjay Kumar Singh retires on superannuation effective 1 November 2026. Deepali Masirkar joins as Executive Director on deputation from 28 October 2026.